Detalles de la búsqueda
1.
The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
Diabetes Obes Metab
; 25(11): 3079-3092, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37551549
2.
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
Diabetes Obes Metab
; 25(5): 1385-1397, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36700417
3.
Microbiome composition and central serotonergic activity in patients with depression and type 1 diabetes.
Eur Arch Psychiatry Clin Neurosci
; 2023 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37847374
4.
Gut microbiota differs in composition between adults with type 1 diabetes with or without depression and healthy control participants: a case-control study.
BMC Microbiol
; 22(1): 169, 2022 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35764926
5.
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
Diabetes Obes Metab
; 24(7): 1338-1350, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35373893
6.
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
Diabetes Obes Metab
; 24(4): 684-692, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34957654
7.
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment.
Diabetes Obes Metab
; 24(5): 806-815, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984794
8.
Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.
Diabetes Obes Metab
; 23(10): 2344-2353, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34189834
9.
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Lancet
; 394(10192): 39-50, 2019 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31186120
10.
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
Diabetes Obes Metab
; 22(8): 1263-1277, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32267058
11.
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Diabetes Obes Metab
; 22(4): 699-704, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750601
12.
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(4): 599-611, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31793165
13.
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
Diabetes Obes Metab
; 21(5): 1081-1087, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30609236
14.
Increased incidence of GERD in GLP-1 treated patients: fact or artefact?
Gut
; 2023 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37857478
15.
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Circulation
; 136(9): 849-870, 2017 Aug 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-28847797
16.
Incretin hormones: Their role in health and disease.
Diabetes Obes Metab
; 20 Suppl 1: 5-21, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29364588
17.
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
Diabetes Obes Metab
; 25(4): 1130-1135, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36562481
18.
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Diabetes Obes Metab
; 20(12): 2821-2829, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29974618
19.
Impact of insulin glargine and lixisenatide on ß-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.
Diabetes Obes Metab
; 19(11): 1625-1629, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28407415
20.
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
Diabetes Obes Metab
; 19(2): 216-227, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717195